A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report
A 66-year-old female patient presenting with dysphagia was diagnosed with stage IV unresectable gastric cancer (cTxN+M1). Multiple liver metastases were identified. The patient subsequently underwent five courses of chemotherapy and immunotherapy, including the capecitabine plus oxaliplatin (XELOX)...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2406061 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717370700955648 |
|---|---|
| author | Li-Ping Sheng Yun-Lin Huang Zhi Wang Hai-Fang Zhang Jin-Yan Zhang Xiao-Yi Lei |
| author_facet | Li-Ping Sheng Yun-Lin Huang Zhi Wang Hai-Fang Zhang Jin-Yan Zhang Xiao-Yi Lei |
| author_sort | Li-Ping Sheng |
| collection | DOAJ |
| description | A 66-year-old female patient presenting with dysphagia was diagnosed with stage IV unresectable gastric cancer (cTxN+M1). Multiple liver metastases were identified. The patient subsequently underwent five courses of chemotherapy and immunotherapy, including the capecitabine plus oxaliplatin (XELOX) regimen combined with tislelizumab. After fifth course treatment, it was confirmed that the liver metastases had completely disappeared and the primary tumor had significantly reduced in size. Consequently, a laparoscopy was performed, revealing a retraction-like response in the primary tumor and no obvious metastases in the abdominal cavity. Subsequently, a radical total gastrectomy was carried out through open abdominal surgery. Pathological analysis showed no remaining cancer or lymph node metastases, and the tumor regression was classified as grade 0. The patient has been now receiving additional chemotherapy and immunotherapy to manage any potential residual metastases. This case illustrated the rare and significant impact of combining chemotherapy with tislelizumab, transitioning the treatment approach from palliative to curative. It highlighted the critical role of immunotherapy in managing advanced gastric cancer with liver metastases. |
| format | Article |
| id | doaj-art-aa0834e69a6c4b02a1d3eb02ad2fce71 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-aa0834e69a6c4b02a1d3eb02ad2fce712025-08-20T03:12:41ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2406061A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case reportLi-Ping Sheng0Yun-Lin Huang1Zhi Wang2Hai-Fang Zhang3Jin-Yan Zhang4Xiao-Yi Lei5Department of Gastroenterology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, ChinaDepartment of Gastroenterology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, ChinaDepartment of Anesthesiology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, ChinaDepartment of Pathology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, ChinaDepartment of Gastroenterology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, ChinaDepartment of Gastroenterology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, ChinaA 66-year-old female patient presenting with dysphagia was diagnosed with stage IV unresectable gastric cancer (cTxN+M1). Multiple liver metastases were identified. The patient subsequently underwent five courses of chemotherapy and immunotherapy, including the capecitabine plus oxaliplatin (XELOX) regimen combined with tislelizumab. After fifth course treatment, it was confirmed that the liver metastases had completely disappeared and the primary tumor had significantly reduced in size. Consequently, a laparoscopy was performed, revealing a retraction-like response in the primary tumor and no obvious metastases in the abdominal cavity. Subsequently, a radical total gastrectomy was carried out through open abdominal surgery. Pathological analysis showed no remaining cancer or lymph node metastases, and the tumor regression was classified as grade 0. The patient has been now receiving additional chemotherapy and immunotherapy to manage any potential residual metastases. This case illustrated the rare and significant impact of combining chemotherapy with tislelizumab, transitioning the treatment approach from palliative to curative. It highlighted the critical role of immunotherapy in managing advanced gastric cancer with liver metastases.https://www.tandfonline.com/doi/10.1080/21645515.2024.2406061Conversion surgerytislelizumabR0 resectionunresectable gastric cancer |
| spellingShingle | Li-Ping Sheng Yun-Lin Huang Zhi Wang Hai-Fang Zhang Jin-Yan Zhang Xiao-Yi Lei A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report Human Vaccines & Immunotherapeutics Conversion surgery tislelizumab R0 resection unresectable gastric cancer |
| title | A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report |
| title_full | A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report |
| title_fullStr | A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report |
| title_full_unstemmed | A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report |
| title_short | A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report |
| title_sort | pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases a case report |
| topic | Conversion surgery tislelizumab R0 resection unresectable gastric cancer |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2406061 |
| work_keys_str_mv | AT lipingsheng apathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport AT yunlinhuang apathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport AT zhiwang apathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport AT haifangzhang apathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport AT jinyanzhang apathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport AT xiaoyilei apathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport AT lipingsheng pathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport AT yunlinhuang pathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport AT zhiwang pathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport AT haifangzhang pathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport AT jinyanzhang pathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport AT xiaoyilei pathologicalcompleteresponsetocapecitabineplusoxaliplatinregimencombinedwithtislelizumabinadvancedgastriccancerwithlivermetastasesacasereport |